Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting
-
Correspondence: David W Miles d.miles@icrf.icnet.uk
Breast Cancer Res 2001, 3:380-384 doi:10.1186/bcr326
Accesses
- Last 30 days: 57 accesses
- Last 365 days: 619 accesses
- All time: 11303 accesses
Cited by
BioMed Central: 1 citation
|
Commentary
Finding the needle in the haystack: why high-throughput screening is good for your health G Wynne Aherne, Edward McDonald, Paul Workman Breast Cancer Res 2002, 4:148-154 (10 June 2002) |
